deltatrials
Recruiting PHASE4 INTERVENTIONAL 3-arm NCT05569382

Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy (TEMPO II)

Sponsor: Morten Steen Kvistholm Jensen

Updated 5 times since 2022 Last updated: Mar 17, 2025 Started: Aug 10, 2022 Primary completion: Apr 1, 2027 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05569382, this PHASE4 trial focuses on Non-obstructive Hypertrophic Cardiomyopathy and remains actively recruiting participants. Sponsored by Morten Steen Kvistholm Jensen, it has been updated 5 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Nov 2022 – ~Jan 2023 · 2 months · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshotRecruiting~Apr 2025 – present · 16 months · monthly snapshotRecruiting

Change History

5 versions recorded
  1. Apr 2025 — Present [monthly]

    Recruiting PHASE4

  2. Sep 2024 — Apr 2025 [monthly]

    Recruiting PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE4

  4. Jan 2023 — Jul 2024 [monthly]

    Recruiting PHASE4

  5. Nov 2022 — Jan 2023 [monthly]

    Recruiting PHASE4

    First recorded

Aug 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Morten Steen Kvistholm Jensen
  • Odense University Hospital
  • Viborg Regional Hospital
  • Zealand University Hospital
Data source: Aarhus University Hospital Skejby

For direct contact, visit the study record on ClinicalTrials.gov .